Two months after raising CHF23 million, Lausanne-based Lunaphore Technologies has received an additional CHF2 million from the Swiss Entrepreneurs Fund as part of a series C2 round. The proceeds will flow into to market and product expansion.
Lunaphore is developing innovative next-generation equipment for cancer research and tissue diagnostics. With FFeX (Fast Fluidic Exchange) technology, the startup promises to perform assays much faster than standard techniques, and it has demonstrated excellent results in tests with cancer patient samples.
In a recent financing round led by the Japanese strategic investor PHC Holdings Corporation (PHCHD), the life-sciences company recently obtained CHF23 million. The CHF 2M Series C2 financing was provided by the Swiss Entrepreneurs Fund, which invested a total of CHF 5M in the company.
The proceeds of the overall CHF 25M Series C closing will be dedicated to market and product expansion, including a US market entry, the ramp-up of activities in Europe and the development of next-generation of instruments.
“We are very happy to add the Swiss Entrepreneurs Fund, which focuses on high-growth companies with global ambitions, to our investors’ base. Together with the strategic investment from PHCHD that we recently closed, Lunaphore is now backed by very strong institutions to achieve its vision.”
(Press release/ran)
Please login or sign up to comment.
Commenting guidelines